Search Scholars Central
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
Advanced searchHide advanced search
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Research article · 2013 Conference abstract · 31 May 2021 Health economics and patient outcomes of non-myeloablative hematopoietic stem cell transplantation (HSCT) versus disease-modifying therap (DMT) for the relapsing remitting multiple sclerosis in the United States of America
hematopoietic stem cell transplantation (HSCT) and disease-modifying therapies (DMTs) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Importance Hematopoietic stem cell transplantation (HSCT)…
Case report · 2017 Apresoline Promoted Acrolein Reduction in Patient with Relapsing Remitting Multiple Sclerosis
Background: Acrolein has been implicated as an irritating/exacerbating factor in animal models of relapsing-remitting multiple sclerosis. In animal studies, Apresoline (Hydralazine) has acted as a successful acrolein…
Research article · 2015 MRI Directional Diffusivity Values of Cervical Cord White Matter: Multiple Sclerosis Patients Vs. Healthy Controls
pinpoint values and cervical spine locations in Diffusion Tensor Imaging (DTI) which best differentiate relapsing-remitting MS from healthy cases. Methods: 10 relapsing-remitting MS and 8 healthy control patients…
Opinion · 24 Apr 2023 Understanding Multiple Sclerosis: Symptoms, Diagnosis, and Treatment Options.
Conference abstract · 18 Mar 2021 Health economics and patient outcomes of non-myeloablative hematopoietic stem cell transplantation (HSCT) versus disease-modifying therap (DMT) for relapsing remitting multiple sclerosis in the United States of America
hematopoietic stem cell transplantation (HSCT) and disease-modifying therapies (DMTs) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Importance Hematopoietic stem cell transplantation (HSCT)…
Review article · 15 Jan 2021 Brief Note on Multiple Sclerosis
Multiple sclerosis (MS) is the most common potentially disabling disease affecting people
Conference abstract · 2018 Evaluation of immuno modulator effect with lymphopaenia and other side effects in relapsingremitting multiple sclerosis patients using fingolimod: clinical data preliminary results
Background: Fingolimod is a new orally available compound for the treatment of relapsing-remitting MS, which has recently been licensed in many countries worldwide. Fingolimod is an oral sphingosine ... also directly…
Conference abstract · 2016 Glatiramer acetate reveals both remitting and progressive processes in an animal model of relapsingremitting multiple sclerosis
LoPresti (2015) determined the cognitive abilities of mice with relapsing-remitting experimental autoimmune encephalomyelitis (EAE) treated with and without glatiramer acetate (GA) compared with naÃ?¯ve mice. We found…
Article · 2015 Multiple Sclerosis and Work: An Interpretative Phenomenological Analysis of the Perspective of Persons with Early Stage MS
Objective:This study explores the lived experience in their working lives of
Conference abstract · 29 Aug 2020 Defects of the Mitochondrial Genome in Multiple Sclerosis
serve as a disease biomarker. The study included 124 Saudi subjects, 60 patients with relapsing-remitting MS (RRMS) and 64 healthy individuals. Genomic DNA was extracted from peripheral blood
Conference abstract · 4 Jul 2019 The pitfalls of natalizumab discontinuation in patients with multiple sclerosis and their abatement by minimizing washout duration: The results of four clinical studies
Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to dimethyl fumarate: A multicenter retrospective observational study. Mult
Research article · 3 May 2019 Relation Of Anthropometric Characteristics In Women With Different Types Of Ms And Comparison With Health Ones
different types of MS in women. 54 patients with MS in three groups (27- Relapsing-Remitting, 16 secondary progressive, 11 primary progressive) and 20 health women as the control group ... waist to hip ratio and fat…
Research article · 6 Oct 2018 Catheter based treatment of the chronic cerebrospinal insufficiency in patients with multiple sclerosis, a single center experience.
multifactorial etiology involving genetic and environmental factors on three basic clinical forms of behavior: Relapsing-remitting, secondary progressive and primary progressive. Classical descriptions in the nineteenth…
Conference abstract · 12 Oct 2017 Are mast cells the key to multiple sclerosis (MS)?
mast cells survive, and within weeks/months may fully reload, may explain the frequent relapsing-remitting alternating phases
Conference abstract · 30 Jul 2017 Headache in relapse and remission phases of multiple sclerosis: A case-control study
study, we attempted to assess the prevalence of headaches during relapses and remissions of relapsing-remitting MS(RRMS)patients and denote the possible interrelations between headaches and types ... Figure 1. Features…
Conference abstract · 1 Dec 2016 Strategies to overcome intrathecal inflammation in progressive multiple sclerosis
secondary-progressive multiple sclerosis (SPMS) were thought to have significantly less intrathecal inflammation than relapsing-remitting (RRMS) MS. Using functional assays and innovative combinatorial cerebrospinal…
Research article · 2016 Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up
multiple sclerosis, there are still patients who suffer from severe neurological dysfunction in the relapsing-remitting or early progressive forms of the disease. For these patients autologous hematopoietic stem cell…
Research article · 2015 Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting
this study was to compare the efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis patients in real-world clinical setting. Methods: We enrolled 391 patients starting either natalizumab…
Conference abstract · 13 Dec 2013 Clinical effectiveness of an inteferon beta 1a biosimilar: Results from an open-label, multicenter, observational study
openlabel, multicentre, retrospective, observational, postmarketing study. Methods: We evaluated a cohort of all adult relapsing-remitting MS patients from 4 LatinAmerican centers that were treated with BlastoferonÃ?®…
Conference abstract Inhibition of system Xc- transporter attenuates autoimmune inflammatory demyelination
demyelination. We find that pharmacological and genetic inhibition of system Xc- attenuates chronic and relapsing-remitting experimental autoimmune encephalomyelitis (EAE). Remarkably, pharmacological blockade of system…
Conference abstract Polymeric prodrugs: Recent achievements and general strategies
multicentre, retrospective, observational, post-marketing study. Methods: We evaluated a cohort of all adult relapsing-remitting MS patients from 4 Latin- American centers that were treated with Blastoferon ... signifi…
Article · 19 Dec 2025 Two-year Assessment of the Efficacy and Safety of Ocrelizumab in Switching Patients from Other Disease Modifying Therapies
lesions). Results: A total of 460 patients were included: 246 with relapsing-remitting MS (RRMS), 196 Progressive Relapsing MS (PRMS), and 18 PPMS. The patients were 58.6% females with
Conference abstract · 17 Mar 2025 Neuroplasticity and cognitive rehabilitation in multiple sclerosis: Evidence from a polish clinical cohort
with neuroplastic changes. Methodology: A prospective study was conducted involving 45 patients diagnosed with relapsing-remitting MS at the Neurology Department of Jagiellonian University Medical College, Kraków…

